Three years after the first approved CRISPR therapies treated patients with sickle cell disease, the follow-up data has arrived — and it is the rare science story in which the results, cautiously stated, are extraordinary.
The clinical picture
Sickle cell disease is a single-letter typo in the gene for haemoglobin; the edited therapies fix the typo's consequences by switching the body back to a fetal form of the protein. In the treated cohorts, the vaso-occlusive crises that defined patients' lives — episodes of pain compared to torture — have been essentially eliminated in the large majority, with durations of follow-up now measured in years rather than the months of the original trials.
- Crisis-free survival holding in multi-year follow-up
- Hospital admissions down by more than ninety percent in responders
- No editing-related adverse events identified in monitoring programmes
The honest uncertainties
Three questions remain open, and the clinicians involved are admirably specific about them. Durability: gene-edited cells must persist for decades to constitute a lifetime cure, and “years” is not yet “decades”. Long-term surveillance for off-target edits continues, and so far is clean. And fertility: the conditioning chemotherapy that precedes editing carries known reproductive costs, which is why fertility preservation is now part of the standard care pathway.
The access problem is the story now
The clinical triumph is shadowed by an economic problem: the therapies launched at prices in the millions per patient, and the world's sickle cell population is overwhelmingly in countries where those prices are fantasy. The interesting developments are logistical: simplified conditioning protocols that can be administered in regional hospitals rather than flagship centres, and technology-transfer agreements piloting local manufacturing of the editing components. Cure, it turns out, is a biological milestone. Access is an engineering one.